Ophthotech Corporation (ISEE)
(Delayed Data from NSDQ)
$1.43 USD
+0.08 (5.93%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.43 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[ISEE]
Reports for Purchase
Showing records 21 - 40 ( 107 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
GA Secondary to AMD Hope in Sight-Looking to 2023; Reit. Buy and $35 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Industry: Medical - Biomedical and Genetics
Zimura Breaking on Through to the Other Side
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Zimura Breaking on Through to The Other Side
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Zimura Breaking on Through to The Other Side
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Asserting Zimura-NDA Submission for Rolling Review in GA dAMD; Reit. Buy; PT to $35
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Interpreting Positive GATHER2 Top-Line-Next Steps NDA Expected 1Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Zimura Well-Positioned For Phase 3 GATHER2 Readout Expected This September
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M